The AI Revolutionizing Drug Trials: Covenant's Bet on Hill Research

PRINCETON, N.J. – July 01, 2026 – In a move that signals deep conviction in the transformative power of artificial intelligence within the life sciences, Covenant Venture Capital has made a significant follow-on investment in Hill Research. The Princeton-based company is the developer of TriClick, an AI platform that is radically accelerating one of the most critical and time-consuming phases of drug development: clinical trial biostatistics and regulatory submissions. The investment, which includes participation from the New Jersey Economic Development Authority (NJEDA) Evergreen Innovation Fund, is not a speculative leap but a calculated decision based on staggering performance metrics, including a fourfold revenue increase from 2024 to 2025.

An Engine of Radical Efficiency

The bottleneck in bringing new treatments to market is often not in the laboratory but in the data. After a clinical trial is complete, pharmaceutical companies face the monumental task of processing, analyzing, and formatting vast datasets into submission-ready packages for regulatory bodies like the FDA. This process, traditionally reliant on manual statistical programming, is laborious, expensive, and prone to human error. Hill Research's TriClick platform is engineered to dismantle this bottleneck. By automating the entire pipeline from a locked clinical database to a final FDA filing, the platform delivers unprecedented speed and precision.

The company reports that its technology can generate complete Tables, Figures, and Listings (TFL) packages—a core component of any clinical submission—up to 300 times faster than manual methods. This is achieved with what the company calls "agentic AI," a system of intelligent, modular agents that manage the data lifecycle with over 99% accuracy. Critically, the platform produces fully traceable and 100% CDISC-compliant outputs, ensuring that the accelerated results meet the stringent standards required for regulatory inspection. For an industry where every day of delay can cost millions and postpone patient access to vital therapies, this fusion of speed and compliance represents a paradigm shift. "Hill Research exemplifies the kind of Deep Tech innovation we champion - an AI-first engine that automates regulated clinical trial data and statistics workflows while producing submission-grade outputs," said René Bastón, Venture Partner at Covenant. "That fusion of agentic AI and experienced biostatistics teams reduces cycle time and mitigates risk for pharma companies, contract research organizations, and functional service providers."

A Calculated Bet on Proven Execution

Covenant's decision to double down on its investment is a direct reflection of its guiding philosophy, which prioritizes "structure, discipline, and long-term conviction over short-term momentum." The venture firm's reinvestment was triggered by Hill Research's demonstrated ability to execute. The fourfold revenue surge and a doubling of its enterprise value in just one year provided concrete evidence that TriClick is not just a promising technology but a commercially viable solution addressing a profound market need. With the new capital, Hill Research is projecting an additional 5-to-8-times revenue growth in 2026, supported by accelerating adoption across the pharmaceutical and biotech sectors.

The investment arrives as the market for AI in clinical trials is experiencing explosive growth. Valued at approximately $2 billion in 2024, some analysts project the market could soar to over $30 billion by 2034. This trend reflects a broader industry-wide push to leverage technology to de-risk and accelerate drug development. Hill Research's success, validated by its adoption by several top-10 global pharma companies, positions it as a key player in this rapidly expanding field. The company is not just selling software; it is offering a scalable and compliant infrastructure that transforms a historically unpredictable workflow into a measurable and auditable process.

Fueling New Jersey's Innovation Economy

The participation of the NJEDA's Evergreen Innovation Fund highlights a successful model of public-private partnership aimed at catalyzing regional economic growth. The fund was specifically designed to co-invest alongside professional venture firms to retain and nurture high-growth companies within the state. By backing Covenant's investment, the NJEDA is ensuring that a pioneering company like Hill Research continues to scale its operations, create high-skilled jobs, and solidify New Jersey's reputation as a burgeoning hub for both life sciences and artificial intelligence. "We're thrilled to do this in New Jersey, where our partnership with NJEDA is catalyzing founders, capital access, and good jobs across the innovation economy," Bastón added.

This strategic support provides more than just capital. It integrates Hill Research into a state-supported ecosystem designed to foster long-term success. For Hill Research's Founder and CEO, Louise Liu, this partnership is a critical enabler. "With Covenant Venture Capital and NJEDA's Evergreen program behind us, we're positioned to continue to scale our platform, grow our clinical trial data and statistics, and FSP capabilities, and deliver even greater impact for patients and the industry," Liu stated. This local support, combined with international recognition at premier AI conferences, provides a powerful foundation for the company's ambitious growth targets.

Navigating the Future of Regulated AI

As AI becomes more deeply embedded in mission-critical industries, the challenges of governance, ethics, and trust move to the forefront. In the highly regulated world of clinical research, these are not abstract concerns but fundamental requirements. The industry is grappling with issues of data privacy, algorithmic bias, and the "black box" problem, where an AI's decision-making process is opaque. Regulatory bodies like the FDA are actively developing frameworks to ensure that AI-driven tools are safe, effective, and equitable.

Hill Research appears to be building its platform with these challenges in mind. The emphasis on full traceability and auditable outputs directly addresses the need for transparency. By maintaining human oversight in a system of supervised automation, the company ensures that expert judgment remains central to the process, with AI handling the scale and consistency. As CEO Louise Liu has noted, the ultimate differentiator will be systems that regulators can inspect and organizations can trust. In an era defined by rapid technological advancement, building that trust may be the most valuable asset of all.